Phage display technology, recombinant

Obviously, phage display technology requires the protein to be properly folded and stable as a fusion with the coat protein. Successful display may depend on the bacterial host and on growth conditions. General strategies to improve recombinant protein expression in E.coli [36] should be transposable to the phage display context. 

Barkhordarian H, Emadi S, Schulz P, Sierks MR (2006) Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng Des Sel 19 497-502. 

Humira [EU and US also sold as Trudexa in EU Adalimumab recombinant (anti-TNF) human mAb created using phage display technology] Cambridge Antibody Technologies and Abbott (US), and Abbott (EU) rheumatoid arthritis 2002 (US), 2003 (EU)... 

Adalimimab (Humira) is another anti-TNF product for intravenous use. This recombinant human IgGj monoclonal antibody was created by phage display technology and is approved for use in rheumatoid arthritis. 

Antirheumatic, Immunomodulatory. Created using phage display technology. Has human-derived heavy- and light-chain variable regions and human constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system. 

The diversity of antibodies can be increased further with phage display libraries and recombinant DNA technology. In recombinant DNA... 

With the advent of recombinant DNA technology, antibody genes can be amplified and selected through phage display, cell-surface display, or cell-free display systems (i.e., ribosome display). A major advantage shared by these systems is the direct... 

There are currently 18 monoclonal antibodies which have been licensed for therapeutic use and this therapeutic category is expanding rapidly. The majority of these antibodies have been produced by recombinant DNA technology such as the phage display system but there are three which are produced by the more old-fashioned murine antibody technology produced in hybridomas. There is currently quite a number of Fab fragments in clinical trials. 

---